Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache

Ömer Karadaş, Hakan L Gül, Levent E Inan, Ömer Karadaş, Hakan L Gül, Levent E Inan

Abstract

Background: The present study aimed to evaluate the efficacy of local lidocaine injections into the myofascial trigger points (TPs) located at the pericranial muscles in patients with episodic tension-type headache (ETTH).

Methods: The study included 108 patients with frequent ETTH that were randomized into 4 groups. One injection of saline (NaCl 0.9%) was administered to group 1 (n = 27), 1 injection of lidocaine (0.5%) was administered to group 2 (n = 27), group 3 (n = 27) received 5 injections of saline (NaCl 0.9%), and group 4 (n = 27) received 5 injections of lidocaine (0.5%); on alternate days 2 mL for each muscle was injected into the frontal, temporal, masseter, sternocleidomastoid, semispinalis capitis, trapezius and splenius capitis muscles bilaterally. The frequency of painful days per month (FPD) and the patients' visual analogue scales (VAS) were evaluated before treatment, and 2, 4 and 6 months after treatment.

Results: Mean age of the patients was 36.28 ± 9.41 years (range: 18-54 years). FPD scores improved significantly in group 2, 3 and 4 at 2 months posttreatment compared to pre- treatment (all P < 0.05), and also VAS scores improved significantly in group 2 and 4 at 2 months posttreatment (P < 0.05) but this improvement insisted at the 6 month only in group 4. Group 2 had better VAS and FPD than group 1 only at 2. and 4. months after treatment (for VAS P < 0.0121, P = 0.0232; for FPD P = 0.0003, P = 0.0004, respectively). Group 4 had better scores than group 3 at the 2., 4. and 6. months after treatment in both parameters (all P < 0.05). Group 2 had better scores than group 1 in FPD at the 2. and 4. months posttreatment (P = 0.0003, P = 0.0004, respectively), but not at the 6. month.

Conclusion: Local lidocaine injections into the myofascial TPs located in the pericranial muscles could be considered as an effective alternative treatment for ETTH.

Figures

Figure 1
Figure 1
An illustration of all groups, the distribution of values for visual analogue scale (VAS): (A) before treatment and (B) 2 months after treatment.
Figure 2
Figure 2
Graph showing the frequency of painful days before and after treatment in all groups.
Figure 3
Figure 3
An illustration of all groups, the distribution of values for visual analogue scale (VAS) for (A) 4 month after treatment and (B) 6 months after treatment.
Figure 4
Figure 4
Comparison of the frequency of painful days before and after treatment belonging to the group received injection of lidocaine hydrochloride 5 times. A significant decrease in the frequency of painful days after treatment (2, 4 and 6 month) compared to pre-treatment was observed P < 0.001). 2., 4. and 6. Months after the treatment, there was no difference between the frequency of painful days (P > 0.005).

References

    1. Inan LE. Gerilim tip baş ağrıları. Turkiye Klinikleri J Neurol-Special Topics. 2003;14(2):127–132.
    1. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998;14(5):381–383. doi: 10.1001/jama.279.5.381.
    1. Silberstein SD, Lipton RB, Goadsby PJ. Clinical Practice of Headache. 2. Oxford: Martin Dunitz; 2002. Tension-Type Headache: Diagnosis and treatment; pp. 113–128.
    1. Lipton RB, Hamelsky SW. In: Wolff’s Headache and Other Head Pain. 7. Silberstein SD, Lipton RB, Dalessio DJ, editor. New York: Ny. Oxford University Press; 2001. Epidemiology and impact of headache; pp. 85–107.
    1. Olesen J, Langemark M. In: Basic mechanisms of headache. Olesen J, Edvinsson L, editor. Amsterdam: Elsevier; 1988. Mechanisms of tension headache. A speculativehypothesis; pp. 457–461.
    1. Jensen K. In: Adv Pain Res Ther, vol 17. Fricton JR, Awad E, editor. New York: Raven; 1990. Quantification of tenderness by palpitation and use of pressure algometers; pp. 165–181.
    1. Bendtsen L, Schoenen J. In: The Headaches. 3. Olesen J, Goadsby PJ, Ramadan N, editor. Philadelphia: Lippincott Williams & Wilkins; 2005. Synthesis of tension-type headache mechanisms; pp. 677–681.
    1. Schmidt-Wilcke T, Leinisch E, Straube A, Kämpfe N, Draganski B, Diener HC, Bogdahn U, May A. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;14(9):1483–1486. doi: 10.1212/01.wnl.0000183067.94400.80.
    1. Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R. Increased prevalence of tension-type headache over a 12-year period is related to increased pain sensitivity. A population study. Cephalalgia. 2007;14(2):145–152. doi: 10.1111/j.1468-2982.2006.01248.x.
    1. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain. 1993;14(3):241–289. doi: 10.1016/0304-3959(93)90027-M.
    1. Schmidt RF. In: Tension-type headache: classification, mechanisms and treatment. Olesen J, Schoenen J, editor. New York: Raven; 1993. Sensitization of peripheral nocisensors in muscle; pp. 47–59.
    1. Jensen R, Olesen J. Initiating mechanisms of experimentally induced tension-type headache. Cephalalgia. 1996;14(3):175–182. doi: 10.1046/j.1468-2982.1996.1603175.x.
    1. Hu JW, Sessle BJ, Raboisson P, Dallel R, Woda A. Stimulation of craniofacial muscle afferents induces prolonged facilitatory effects in trigeminal nociceptive brain-stem neurones. Pain. 1992;14(1):53–60. doi: 10.1016/0304-3959(92)90131-T.
    1. Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, Karageorgiou K. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia. 2007;14(4):315–324. doi: 10.1111/j.1468-2982.2007.01300.x.
    1. Silver N. Headache (chronic tension-type) Am Fam Physician. 2007;14(1):114–116.
    1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;14(suppl1):16–22.
    1. Jaeger B. In: Head and Neck Pain, Travell & Simons’Myofascial pain and dysfunction the triger point manual. II. Simons DG, Travell JG, Simons LS, editor. Pennsylvania: Lippincott Williams&Wilkins; 1999. pp. 237–484.
    1. Kayaalp O. Lokal Anestezikler: in Kayaalp O (ed): Kayalalp Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, ed 10. Hacettepe-TAŞ: Ankara; 2002. pp. 792–806.
    1. Catterall WA, Kenneth M. In: Goodman & Gilman's the pharmacological basis of therapeutics. 11. Brunton LL, Lazo JS, Parker KKL, editor. Texas: The Mcgraw-hill Mompanies Inc; 2006. local anesthetics; pp. 241–251.
    1. Bendtsen L. Central sensitization in tension-type headache-possible pathophysiological mechanisms. Cephalalgia. 2000;14(5):486–508. doi: 10.1046/j.1468-2982.2000.00070.x.
    1. Jensen R. Peripheral and central mechanisms in tension-type headache: an update. Cephalalgia. 2003;14(Suppl 1):49–52.
    1. Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol. 2005;14(5):1977–1984. doi: 10.1152/japplphysiol.00419.2005.
    1. Venâncio Rde A, Alencar FG, Zamperini C. Different substances and dry-needling injections in patients with myofascial pain and headaches. Cranio. 2008;14(2):96–103.
    1. Huguenin KL. Myofascial trigger points: the current evidence. Phys Ther Sport. 2004;14(1):2–12. doi: 10.1016/j.ptsp.2003.11.002.
    1. Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011;14(2):185–198. doi: 10.1016/j.berh.2011.01.002.
    1. Venancio Rde A, Alencar FG Jr, Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches. Cranio. 2009;14(1):46–53.
    1. Calandre EP, Hidalgo J, Garcia-Leiva JM, Rico-Villademoros F, Delgado-Rodriguez A. Myofascial trigger points in cluster headache patients: a case series. Head Face Med. 2008;14:32. doi: 10.1186/1746-160X-4-32.
    1. Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, Di Ianni L, Lapenna D, Mezzetti A. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007;14(11):869–878. doi: 10.1016/j.jpain.2007.06.002.
    1. Tfelt-Hansen P, Olesen J, Lous I. Lignocaine versus saline in migraine pain. Lancet. 1980;14(8178):1140.
    1. García-Leiva JM, Hidalgo J, Rico-Villademoros F, Moreno V, Calandre EP. Effectiveness of ropivacaine trigger points inactivation in the prophylactic management of patients with severe migraine. Pain Med. 2007;14(1):65–70. doi: 10.1111/j.1526-4637.2007.00251.x.
    1. Martín-Herrero C, de Souza DP R, Alburquerque-Sendín F, Ortega-Santiago R, Fernández-de-Las-Peñas C. Myofascial trigger points, pain, disability and quality of sleep in patients with chronic tension-type headache: a pilot study. Rev Neurol. 2012;14(4):193–199.
    1. Alonso-Blanco C, de-la-Llave-Rincón AI, Fernández-de-las-Peñas C. Muscle trigger point therapy in tension-type headache. Expert Rev Neurother. 2012;14(3):315–322. doi: 10.1586/ern.11.138.
    1. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Incidence of primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol. 2005;14(11):1066–1073. doi: 10.1093/aje/kwi139.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する